These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30797713)

  • 21. WT-1 in ovarian and endometrioid serous carcinoma: a meta-analysis.
    Heatley MK
    Histopathology; 2005 Apr; 46(4):468. PubMed ID: 15810962
    [No Abstract]   [Full Text] [Related]  

  • 22. Tubo-ovarian high-grade serous carcinomas commonly express CA19.9.
    Rajendran S; McCluggage WG
    Histopathology; 2022 Jan; 80(2):449-450. PubMed ID: 34268810
    [No Abstract]   [Full Text] [Related]  

  • 23. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
    Chen X; Wang X; Wei X; Wang J
    J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of ovarian cancer cell secretome during epithelial to mesenchymal transition reveals a protein signature associated with advanced stages of ovarian tumors.
    Lanfredi GP; Thomé CH; Ferreira GA; Silvestrini VC; Masson AP; Vargas AP; Grassi ML; Poersch A; Candido Dos Reis FJ; Faça VM
    Biochim Biophys Acta Proteins Proteom; 2021 Jun; 1869(6):140623. PubMed ID: 33607274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retroperitoneal vascular leakage in ovarian cancer is associated with increased VEGF.
    Rodewald M; Herr D; Schmitt W; Konrad R; Kreienberg R; Wulff C
    Gynecol Oncol; 2008 Jan; 108(1):251-2. PubMed ID: 17919701
    [No Abstract]   [Full Text] [Related]  

  • 26. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.
    Tung CS; Mok SC; Tsang YT; Zu Z; Song H; Liu J; Deavers MT; Malpica A; Wolf JK; Lu KH; Gershenson DM; Wong KK
    Mod Pathol; 2009 Sep; 22(9):1243-50. PubMed ID: 19525924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
    Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
    Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions.
    Nakamura K; Nakayama K; Ishibashi T; Ishikawa N; Ishikawa M; Katagiri H; Minamoto T; Sato E; Sanuki K; Yamashita H; Iida K; Sultana R; Kyo S
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expression of THY1 gene in epithelial ovarian cancer].
    Zeng LQ; Peng ZL; Duan ZL
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):118-20. PubMed ID: 19538887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of leukaemia inhibitory factor in epithelial ovarian carcinoma: correlation with clinical characteristics.
    Ye F; Hu Y; Lu W; Zhou C; Xie X
    Histopathology; 2008 Aug; 53(2):224-8. PubMed ID: 18540977
    [No Abstract]   [Full Text] [Related]  

  • 32. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
    Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile.
    Zheng M; Mullikin H; Hester A; Czogalla B; Heidegger H; Vilsmaier T; Vattai A; Chelariu-Raicu A; Jeschke U; Trillsch F; Mahner S; Kaltofen T
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
    Wen J; Shi JL; Shen DH; Chen YX; Song QJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
    Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Updates on histologic grading and pathogenesis of ovarian serous carcinomas].
    Shen Y; Yang F; Liu JS
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):507-10. PubMed ID: 22169636
    [No Abstract]   [Full Text] [Related]  

  • 38. Non-neoplastic Fallopian Tube Epithelium Carrying Gene Mutations of a Novel SOX2 Repressor Region is Soil of High-grade Serous Ovarian Cancer.
    Hirohashi Y; Torigoe T
    EBioMedicine; 2016 Aug; 10():17-8. PubMed ID: 27423191
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients.
    Moilanen J; Lassus H; Leminen A; Vaheri A; Bützow R; Carpén O
    Gynecol Oncol; 2003 Aug; 90(2):273-81. PubMed ID: 12893187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.